Enterprise Value
616M
Cash
27.14M
Avg Qtr Burn
-3.499M
Short % of Float
1.13%
Insider Ownership
25.37%
Institutional Own.
1.28%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Olvi-Vec (Olvimulogene nanivacirepvec) + platinum-doublet + bevacizumab Details Ovarian cancer, Cancer, Platinum-resistant ovarian cancer | Phase 3 Data readout | |
Olvi-Vec (Olvimulogene nanivacirepvec) Details Cancer, Small cell lung cancer | Phase 1 Data readout |